Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support

被引:23
|
作者
Shelton, Jeremy B. [1 ,2 ]
Ochotorena, Lee [1 ]
Bennett, Carol [1 ,2 ]
Shekelle, Paul [1 ]
Kwan, Lorna [2 ]
Skolarus, Ted [3 ]
Goldzweig, Caroline [1 ]
机构
[1] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA
[3] Vet Adm Ann Arbor Healthcare Syst, Hlth Serv Res & Dev, Ann Arbor, MI USA
关键词
electronic health records; physician decision support; cancer screening; applied informatics; implementation research; quality improvement; HEALTH INFORMATION-TECHNOLOGY; CARE; MORTALITY; ALERTS; INTERVENTIONS; PHYSICIANS; IMPLEMENT; BENEFITS; QUALITY; COSTS;
D O I
10.1007/s11606-015-3249-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In 2012, the Veterans Health Administration (VHA) implemented guidelines seeking to reduce PSA-based screening for prostate cancer in men aged 75 years and older. To reduce the use of inappropriate PSA-based prostate cancer screening among men aged 75 and over. The Veterans Affairs Greater Los Angeles Healthcare System (VA GLA) We developed a highly specific computerized clinical decision support (CCDS) alert to remind providers, at the moment of PSA screening order entry, of the current guidelines and institutional policy. We implemented the tool in a prospective interrupted time series study design over 15 months, and compared the trends in monthly PSA screening rate at baseline to the CCDS on and off periods of the intervention. A total of 30,150 men were at risk, or eligible, for screening, and 2,001 men were screened. The mean monthly screening rate during the 15-month baseline period was 8.3 %, and during the 15-month intervention period, was 4.6 %. The screening rate declined by 38 % during the baseline period and by 40 % and 30 %, respectively, during the two periods when the CCDS tool was turned on. The screening rate ratios for the baseline and two periods when the CCDS tool was on were 0.97, 0.78, and 0.90, respectively, with a significant difference between baseline and the first CCDS-on period (p < 0.0001), and a trend toward a difference between baseline and the second CCDS-on period (p = 0.056). Implementation of a highly specific CCDS tool alone significantly reduced inappropriate PSA screening in men aged 75 years and older in a reproducible fashion. With this simple intervention, evidence-based guidelines were brought to bear at the point of care, precisely for the patients and providers for whom they were most helpful, resulting in more appropriate use of medical resources.
引用
收藏
页码:1133 / 1139
页数:7
相关论文
共 50 条
  • [1] Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support
    Jeremy B. Shelton
    Lee Ochotorena
    Carol Bennett
    Paul Shekelle
    Lorna Kwan
    Ted Skolarus
    Caroline Goldzweig
    Journal of General Internal Medicine, 2015, 30 : 1133 - 1139
  • [2] Reducing inappropriate PSA-based prostate cancer screening in men age 75 or older with a highly specific computerized clinical decision support tool.
    Shelton, Jeremy B.
    Ochotorena, Lee
    Bennett, Carol J.
    Shekelle, Paul
    Goldzweig, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)
  • [3] Capsule Commentary on Shelton et al., Reducing PSA-Based Prostate Cancer Screening in Men ≥ 75 Years Old with Highly Specific Computerized Clinical Decision Support
    Sarah Patricia Slight
    Journal of General Internal Medicine, 2015, 30 : 1187 - 1187
  • [4] Capsule Commentary on Shelton et al., Reducing PSA-Based Prostate Cancer Screening in Men aparts per thousandyen 75 Years Old with Highly Specific Computerized Clinical Decision Support
    Slight, Sarah Patricia
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2015, 30 (08) : 1187 - 1187
  • [5] Clinician interest in clinical decision support for PSA-based prostate cancer screening
    Harper, Jonathan
    Hunt, Trevor
    Choudry, Mouneeb
    Kapron, Ashley L.
    Cooney, Kathleen A.
    Martin, Christopher
    Ambrose, Jacob
    O'Neil, Brock
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (03) : 145.e17 - 145.e23
  • [6] Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality
    Hoffman, Richard M.
    ANNALS OF INTERNAL MEDICINE, 2012, 157 (02)
  • [7] ERSPC Trial - PSA(prostate-specific Antigen)-based Prostate Cancer Screening in older Men
    Radtke, Jan Philipp
    Handke, Analena Elisa
    Haidl, Friederike
    Albers, Peter
    UROLOGIE, 2024, 63 (11): : 1155 - 1157
  • [8] PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making
    Venderbos, Lionne D. F.
    Roobol, Monique J.
    ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (02) : 219 - 224
  • [9] EVALUATION OF PREBIOPSY MAGNETIC RESONANCE IMAGING COMBINED WITH PROSTATE-SPECIFIC ANTIGEN DENSITY IN THE DIAGNOSIS OF PROSTATE CANCER IN MEN AGED 75 YEARS AND OLDER WITH ELEVATED PSA
    Yanai, Yoshinori
    Kosaka, Takeo
    Teranishi, Yu
    Hattori, Seiya
    Matsumoto, Kazuhiro
    Morita, Shinya
    Shinoda, Kazunobu
    Shinojima, Toshiaki
    Mizuno, Ryuichi
    Kikuchi, Eiji
    Mikami, Shuji
    Jinzaki, Masahiro
    Miyajima, Akira
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2017, 197 (04): : E753 - E753
  • [10] Screening for Prostate Cancer among Men 75 Years of Age or Older.
    Barry, Michael J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (24): : 2515 - 2516